Print

Hyperion Therapeutics to Report Results of HALT-HE Study at American Association for Study of Liver Diseases Plenary Session  
10/3/2012 9:52:00 AM

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the HALT-HE Study will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver MeetingĀ®), taking place on November 9-13, 2012 in Boston, MA. The presentation, "Randomized, controlled, double-blind study of glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy," will be made on Monday, November 12, 2012, at 8:45 a.m. ET in the Presidential Plenary Session I in the Hynes Convention Center Auditorium.
//-->